← Leaderboards
Aaron D Schuler
Syntrix Biosystems, Inc.
$1,538,086
Attributed
$3,076,172
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$3,076,172 · 2
By mechanism
R44$3,076,172 · 2
Top collaborators
- John A Zebala5 shared
Most similar at Syntrix Biosystems, Inc.
Same institution · by research overlap
- John A Zebala$18,699,047
- Dean Yoshimasa Maeda$6,126,552
Others in their field
Other Rising Stars on “Pharmaceutical Preparations”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Suma Babu · Massachusetts General Hospital$15,344,018
- Sabrina Paganoni · Massachusetts General Hospital$15,344,018
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
Pharmaceutical PreparationsSmall MoleculeIl8 GeneParticipant EnrollmentRefractorySmall Business Innovation Research GrantDoseExhibitsIl8rb GeneManufacturePre-ClinicalPublishingResearch Clinical TestingResistanceClinical Research SiteCohortDysmyelopoietic SyndromesEnrollmentCancer ModelIl8ra GeneInhibitorLigandsChemokine ReceptorBinding
Grant awards (5)
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$903,852
R44 · FY2025 · CA · contact PI
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$627,270
R44 · FY2025 · CA · contact PI
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$745,050
R44 · FY2024 · CA · contact PI
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$400,000
R44 · FY2024 · CA · contact PI
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$400,000
R44 · FY2023 · CA · contact PI